BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that the Cancer Treatment Centers of America (CTCA) hospital at Eastern Regional Medical Center, located in Philadelphia, Pennsylvania, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Philadelphia is a state-of-the-art hospital that provides advanced cancer treatments, world-class technologies, and supportive therapies under one roof. CTCA in Philadelphia provides the most advanced therapeutic resources in cancer treatment (http://www.cancercenter.com/eastern-hospital.cfm). CTCA is a network of hospitals and one of the premier providers of cancer care in the world. Like all CTCA cancer hospitals, the Philadelphia facility provides an unsurpassed environment of healing and hope. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care." This will be the fifth BSD Hyperthermia system purchased by CTCA, including three systems purchased within the last five months.
"After successfully performing superficial hyperthermia treatments with the BSD-500 Hyperthermia System at CTCA, we are looking forward to introducing the BSD-2000, with the capacity to treat deep into tissues, to offer our patients even more options to treat their cancer," said Curt Heese, MD, Radiation Oncologist at CTCA in Philadelphia.
CTCA physicians specialize in treating many types of cancer, including complex and advanced stage cases. The cancer experts employed by CTCA work as a team across multiple disciplines to provide an individualized cancer treatment plan designed to treat the whole person. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient's treatment experience and quality of life.
The BSD-2000 - developed and patented exclusively by BSD - delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the 3-dimensional shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 is restricted to investigational use in the US, and the Company is currently conducting a clinical study to evaluate the safety and efficacy of hyperthermia using the BSD-2000 combined with radiotherapy for the treatment of patients suffering from locally advanced, persistent, or recurrent deep tumors of the pelvis; i.e., cervical, prostate, rectal, and bladder. BSD has also applied for a Humanitarian Device Exemption (HDE) approval for its BSD-2000 Hyperthermia System and this submission is still under review by the FDA.
Study shows community health workers can improve asthma care for children